Ryzumvi (phentolamine) is an eye drop used for pharmacologically-induced mydriasis, or more simply, it is used to reverse dilated pupils caused by eye drops used during eye examinations for routine eye check-ups, disease monitoring, or surgical procedures.

Dilated pupils cause sensitivity to light (photophobia) and blurred vision, which may make it difficult to read, work, and drive, which can last 24 hours after the examination. Ryzumvi eye drops are used to speed up the return to normal pupil size, to restore normal vision, and reduce light sensitivity so there is less disruption to daily activities.

Ryzumvi (phentolamine ophthalmic solution) became a FDA-approved medicine on September 27, 2023, to treat pharmacologically-induced mydriasis - dilation of the pupil of the eye caused by eye drops. Approval was supported by positive results in the MIRA-2 and MIRA-3 clinical trials.

During the development of phentolamine ophthalmic solution, it was given the brand name Nyxol which was later changed to Ryzumi.

Ryzumvi should not be used in patients who have active ocular inflammation (uveitis).

Ryzumvi eye drops are instilled into each dilated eye after the eye examination or procedure is finished to reverse pupil dilation.

Adults and pediatric patients aged 12 years or older: Instill 1 or 2 drops in each dilated eye following the completion of the ophthalmic examination or procedure. If 2 drops are instilled, the second drop should be administered 5 minutes after the first drop.

Pediatric patients aged 3 to 11 years:  Instill 1 drop in each dilated eye following the completion of the ophthalmic examination or procedure.

Comment: One single-patient-use vial can be used to dose each dilated eye. Discard the single-patient-use vial immediately after use.
Contact lens wearers should be advised to remove their lenses prior to the instillation of Ryzumvi and wait 10 minutes after dosing before reinserting their contact lenses.

Dosage Form

• Ryzumvi (phentolamine ophthalmic solution) is available in 0.75% single-patient-use vial with a 0.31 mL fill. 
• One strip of 5 single-patient-use vials is packaged into a foil pouch, with 6 foil pouches in a carton. 
• One single-patient-use vial should be dispensed for each patient, and it can be used to dose both eyes.

Pregnancy

Tell your healthcare provider if you are pregnant or plan to become pregnant, as there is no available data with Ryzumvi administration in pregnant women. Ryzumvi should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breastfeeding 

Tell your healthcare provider if you are breastfeeding or planning to breastfeed, as there is no information regarding the presence of Ryzumvi in human milk, the effects on breastfed infants, or the effects on milk production.